Applied Therapeutics, Inc.
APLT
$0.10
-$0.01-7.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | -- | -- | 0.00 | 122.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | -- | -- | 0.00 | 122.00K |
| Cost of Revenue | 9.60M | 9.92M | 7.84M | 11.70M | 14.83M |
| Gross Profit | -8.60M | -9.92M | -7.84M | -11.70M | -14.71M |
| SG&A Expenses | 9.37M | 13.18M | 17.69M | 21.33M | 15.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.97M | 23.10M | 25.53M | 33.02M | 29.87M |
| Operating Income | -17.97M | -23.10M | -25.53M | -33.02M | -29.74M |
| Income Before Tax | -18.99M | -21.33M | -21.83M | 44.01M | -68.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.99M | -21.33M | -21.83M | 44.01M | -68.59M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.99M | -21.33M | -21.83M | 44.01M | -68.59M |
| EBIT | -17.97M | -23.10M | -25.53M | -33.02M | -29.74M |
| EBITDA | -17.97M | -23.10M | -25.52M | -33.02M | -29.74M |
| EPS Basic | -0.13 | -0.15 | -0.15 | 0.30 | -0.48 |
| Normalized Basic EPS | -0.09 | -0.09 | -0.09 | 0.19 | -0.30 |
| EPS Diluted | -0.13 | -0.15 | -0.15 | 0.30 | -0.48 |
| Normalized Diluted EPS | -0.09 | -0.09 | -0.09 | 0.19 | -0.30 |
| Average Basic Shares Outstanding | 145.56M | 145.09M | 144.79M | 144.46M | 144.35M |
| Average Diluted Shares Outstanding | 145.56M | 145.09M | 144.79M | 144.46M | 144.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |